HUM three-lens brief
Evidence-based stock research on HUM. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Trading at 91% of its 52-week range — near the top of the band.
- Trading at 91% of its 52-week range — near the top of the band.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Outperforming SPY by 27.8pp over 30 days.
- Analyst mean target $315.38 — 20% below current (24 analysts).
- Earnings scheduled 2026-07-29.
HUM closed at $392.51 (-1.32%) as of 2026-07-10. Market cap: $47.13B. P/E (trailing) 41.8. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 27.8pp over 30 days.. Concerns: trading at 91% of its 52-week range — near the top of the band.; analyst mean target $315.38 — 20% below current (24 analysts).. Last quarter: Revenue $39.65B, net income $1.19B, free cash flow $1.43B. Watching for: 2026-07-29 earnings release (18 days out).
Why three lenses on HUM, not one.
A single reasoning model has blind spots it doesn’t know about. We examine HUMacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/HUM" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath HUM brief"></iframe>